New antibody could boost cure rate for devastating blood diseases

This study is testing if adding a new antibody drug called briquilimab (JSP191) to a blood stem cell transplant makes the treatment more successful for people with sickle cell disease or beta-thalassemia. The transplant is a potential cure, and researchers want to see if the drug helps the donor's cells take hold better in the patient's body. The trial involves about 40 participants who are at high risk from their disease and have a matched family donor.